Evidence map›Paper›PMID 42394822›Full record

ArticleFrontiers in cellular and infection microbiology2026

STING agonist 2'3'-cGAMP as an effective adjuvant for HPV16 peptide vaccine enhances anti-tumor immunity in TC-1 mice models.

Yina Cun, Rui Yang, Jie Dai, Xinwen Zhang, Lili Zhou, Li Shi, Jing Li, Haocheng He, Shuyuan Liu, Yufeng Yao

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in cellular and infection microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Yina Cun *Department of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Rui Yang *Department of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Jie DaiDepartment of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Xinwen ZhangYunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Lili ZhouDepartment of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Li ShiDepartment of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Jing LiDepartment of Epidemiology and Statistics, West China School of Public Health and West China Fourth Hospital, Sichuan University, Chengdu, China.
Haocheng HeDepartment of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Shuyuan LiuDepartment of Immunogenetics, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.
Yufeng YaoYunnan Key Laboratory of Vaccine Research & Development on Severe Infectious Disease, Institute of Medical Biology, Chinese Academy of Medical Sciences & Peking Union Medical College, Kunming, Yunnan, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Adjuvants are critical for enhancing vaccine immunogenicity. The agonists in cyclic GMP-AMP synthase (cGAS)-stimulator of interferon genes (STING) signaling pathway have demonstrated robust immune activation in preclinical models. Peptide vaccines targeting T cell epitopes of high-risk human papillomavirus (HPV) E6 and E7 represent a promising immunization strategy. To improve immunogenicity, we utilized the STING agonist 2'3'-cGAMP as an adjuvant and evaluated its ability to enhance immune responses and antitumor efficacy. Methods: The immunogenicity and efficacy of a candidate vaccine, consisting of the HPV16 E7 Results: Immunization with the E7 Conclusion: The STING agonist 2'3'-cGAMP serves as an effective adjuvant that enhances the therapeutic efficacy of an HPV16 peptide vaccine. These findings indicate its potential as a candidate therapeutic for HPV16 persistent infection and associated malignancies.

Indexed as

Adjuvants, ImmunologicAdjuvants, VaccineHuman papillomavirus 16Membrane ProteinsNucleotides, CyclicPapillomavirus VaccinesAnimalsCancer VaccinesCell Line, TumorcGAS-STING Signaling PathwayDendritic CellsDisease Models, AnimalEpitopes, T-LymphocyteFemaleInterferon-gammaMiceAdjuvants, ImmunologicAdjuvants, VaccineCancer Vaccinescyclic guanosine monophosphate-adenosine monophosphateEpitopes, T-LymphocyteInterferon-gammaMembrane ProteinsNucleotides, Cycliconcogene protein E7, Human papillomavirus type 16Papillomavirus E7 ProteinsPapillomavirus VaccinesProtein Subunit VaccinesSting1 protein, mouseSTING ProteinVaccines, SubunitadjuvantHPV 16peptide vaccineSTING agoniststherapeutic vaccine

Identifiers

PMID42394822
PMCPMC13323254

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.